Table 2.

Recruitment methods and reasons for study withdrawal.

Author	Study intervention	Recruitment methods	Reasons for withdrawal
Carbonell et al. (2008)13	Mifepristone 5mg vs. 10 mg	Study/clinic personnel	Adverse event
Hehenkamp et al. (2008)14	UAE* vs. hysterectomy	Study/clinic personnel, local newspaper	Patient preferred treatment, declined allocated treatment
Levens et al. (2008)15	CDB-2914 vs. placebo	Study/clinic personnel, media sources, internet postings, community outreach	Declined allocated treatment, pelvic pain, failure to follow-up
Mara et al. (2008)16	UAE* vs. myomectomy	Study/clinic personnel	Patient refused enrollment, exclusion criteria, failure to follow-up
Wilkens et al. (2008)17	Asoprisnil vs. placebo	Study/clinic personnel	Exclusion criteria
Chwalisz et al (2007)18	Asoprisnil vs. placebo	**	Adverse event, protocol violation, withdrawal of consent, failure to follow- up
Hald et al. (2007)19	Laparoscopic occlusion vs. UAE*	Study/clinic personnel	Patient preferred treatment, declined allocated treatment, failure to follow- up
Muneyyirci et al. (2007)20	Pre-op Goserelin vs. Iron monotherapy	**	Adverse reaction to medication, subject non- compliance, withdrawal of consent, failure to follow- up
Fiscella et al. (2006)21	Mifepristone vs. placebo	Study/clinic personnel, local media, community physician referrals	Patient declined following randomization
Mara et al. (2006)22	UAE* vs. myomectomy	Study/clinic personnel	Patients declined enrollment
Donnez et al (2003)23	Fulvestrant vs. goserelin	Study/clinic personnel	Protocol deviation, adverse event
Palomba et al. (2002)24	Leuprolide plus raloxifene vs. leuprolide plus placebo	Study/clinic personnel	Patient non-compliance, failure to follow-up
Verspyck et al. (2000)25	Leuprorelin vs. lynestrenol	**	Adverse event, failure to follow-up, protocol deviation

^*UAE: uterine artery embolization

^**Information not provided